Alzheimer’s – Vielight Inc

Mild Cognitive Impairment (MCI) Clinical Trial Recruitment | University of Toronto | Unity Health Toronto | Vielight Neuro (n=60)

Vielight Main — Wed, 20 Aug 2025 21:39:34 +0000

Do you—or someone you love—notice recent memory changes? You may be eligible for a research study at St. Michael’s Hospital in Toronto. This study investigates PBM therapy, a non-invasive method that uses near-infrared (NIR) light—to see whether it can support brain health in people with memory concerns.

For more details about this MCI clinical trial: https://clinicaltrials.gov/study/NCT06618807

Why this study matters

MCI is a transitional state between normal aging and Alzheimer’s dementia. On average, about 32% of people with MCI progress to dementia, 62% remain stable, and roughly 6% return to normal cognition at later visits. While some medications (e.g., donepezil, galantamine, rivastigmine, memantine) can help with symptoms, there’s still a need for safe options that may support longer-term cognitive function with fewer side effects.

This study investigates PBM therapy—a non-invasive method that uses gentle near-infrared (NIR) light—to see whether it can support brain health in people with memory concerns.

About the study

Device tested: Neuro RX Gamma, a wearable headset with 5 LEDs plus an intranasal applicator (1 LED).
How the device works: The Vielight Neuro delivers 810nm NIR light to targeted brain regions. It is non-thermal (does not produce significant heat) and non-invasive.
Design: 60+ participants will use either an active or sham (placebo-like) Neuro RX Gamma device, allowing researchers to compare outcomes fairly.
Duration: 12 weeks total.
Location: Toronto.

Important: PBM is being studied here to understand potential benefits; it is not an approved treatment for MCI. Participation is voluntary.

Who can apply

You may be a good fit if you:

Are 50 years or older, and
Have noticed memory changes (e.g., forgetfulness, word-finding, misplacing items), without a formal diagnosis of MCI or dementia.
You are able to undergo a blood test and an MRI scan (Exceptions for undergoing MRI may be allowed)

If you’re unsure, the study team can guide you through a brief screening to check eligibility.

What participation looks like

Screening & consent: Undergo an initial assessment to determine eligibility for the study.
Baseline visit: Assessments of memory and thinking, blood draw, and brain MRI (MRI exceptions allowed)
At-home use: 20 minutes daily, 6 days a week, for 8 weeks
Check-ins: Short follow-ups to track how you’re doing.
Post-Trial Evaluation: Repeat assessments to measure any changes over the 8 weeks.
Follow-up visit: 4 weeks after the Post-Trial Evaluation, repeat memory assessments and blood draw to measure lasting effects.

The team will teach you exactly how to place and use the device. LEDs are standard, semiconductor light sources—no surgery, no needles.

Safety

PBM at low levels is generally considered safe and well-tolerated in research settings. As with any study, you’ll be informed of potential risks and can withdraw at any time.

Ready to learn more or sign up?

Phone: 416-360-4000 ext. 47838
Email: memoryclinic@unityhealth.to

When you reach out, you can simply say:

“I’m interested in the photobiomodulation memory study for people over 50.”

Quick FAQ

Is this a treatment?
This is a clinical research study to evaluate PBM; it is not established treatment for MCI.

Do I need a diagnosis first?
No. If you’re over 50 and noticing memory changes—but don’t have a formal diagnosis—you’re welcome to contact the team for screening.

Will I definitely get the active device?
Not necessarily. To ensure fair results, some participants use a sham device. You’ll learn which you had after the study, if applicable.

Can I keep my current medications?
Please tell the study team about any medications. They’ll advise you on eligibility and any required adjustments.

About the Device

The Neuro RX Gamma, a wearable headset with 5 LEDs plus an intranasal applicator (1 LED).

It delivers 810nm NIR light to targeted brain regions. It is non-thermal (does not produce significant heat) and non-invasive.

Safety: PBM at low levels is generally considered safe and well-tolerated in research settings. As with any study, you’ll be informed of potential risks and can withdraw at any time.

Important: PBM is being studied here to understand potential benefits; it is not an approved treatment for MCI. Participation is voluntary.

Share with a friend or family member

If you know someone 50+ who’s been forgetting appointments, repeating questions, or feeling more “foggy” than usual, please share this post. Early participation in research can help advance options for everyone.

This post is for recruitment and general information only. It does not replace medical advice. Speak with your healthcare provider about any concerns regarding your memory or thinking.

The post Mild Cognitive Impairment (MCI) Clinical Trial Recruitment | University of Toronto | Unity Health Toronto | Vielight Neuro (n=60) appeared first on Vielight Inc.

Alzheimer’s Disease and Brain Photobiomodulation | Clinical Results with Vielight Neuro

Vielight Main — Thu, 10 Jul 2025 21:21:44 +0000

This article is based on published independent Alzheimer’s research conducted with the Vielight Neuro Gamma by the University of California

Vielight Neuro Gamma

Read the full Alzheimer’s Disease published study with the Vielight Neuro here: Link

Introduction

Alzheimer’s disease (AD) remains one of the most challenging and devastating neurodegenerative conditions affecting millions worldwide. Characterized by progressive cognitive decline, memory loss, and behavioral changes, AD not only affects the individual but also imposes a significant burden on caregivers and healthcare systems. Despite extensive research, effective treatments for AD are still elusive. However, a promising avenue of investigation has emerged in recent years – brain photobiomodulation (PBM).

Brain PBM, also known as transcranial light therapy or low-level light therapy, involves the non-invasive application of high-power density NIR light energy through the scalp, to the brain, stimulating cellular function and promoting tissue repair. While initially explored for its potential in wound healing and pain management, researchers are increasingly investigating its therapeutic effects on neurological disorders, including AD.

Understanding Alzheimer’s Disease

Before delving into the potential of PBM in AD, it’s crucial to grasp the underlying mechanisms of the disease. AD is characterized by the accumulation of beta-amyloid plaques and tau protein tangles in the brain, leading to neuronal dysfunction and eventual cell death. Additionally, oxidative stress, inflammation, and impaired mitochondrial function contribute to the progression of the disease.

The mechanisms of brain photobiomodulation

How Photobiomodulation Works against Alzheimer’s Disease

When near-infrared light energy penetrates the scalp and skull, reaching neuronal tissue – it is absorbed by mitochondria, enhancing cellular metabolism, increasing ATP production, and reducing oxidative stress and inflammation.

The therapeutic effects of PBM in AD are thought to stem from its ability to modulate various cellular processes implicated in the pathogenesis of the disease.

One key mechanism of PBM against AD is the stimulation of mitochondrial function. Mitochondrial dysfunction is a hallmark of AD and is believed to contribute to neuronal degeneration. By enhancing mitochondrial activity, PBM may help improve cellular energy production and mitigate oxidative stress, thereby protecting neurons from damage.

Besides that, by reducing oxidative stress, PBM may mitigate neuronal damage and promote cellular survival. Oxidative stress arises from an imbalance between the production of reactive oxygen species (ROS) and the body’s ability to detoxify them, leading to cellular damage and dysfunction. PBM has been shown to enhance the activity of antioxidant enzymes, such as superoxide dismutase (SOD) and catalase, while simultaneously reducing the production of ROS. This dual effect helps to restore redox balance within neurons, thereby protecting them from oxidative damage and promoting cellular survival. By targeting oxidative stress, PBM may offer neuroprotective benefits in AD, potentially slowing disease progression and preserving cognitive function.

PBM has also been shown to modulate inflammatory pathways, potentially attenuating neuroinflammation, which is another hallmark of AD. This anti-inflammatory effect of PBM holds significant implications for the treatment of AD, as chronic neuroinflammation contributes to neuronal damage and cognitive decline.

Furthermore, PBM has been shown to promote neurogenesis and synaptogenesis, processes essential for maintaining cognitive function and synaptic plasticity. By stimulating the growth of new neurons and strengthening synaptic connections, PBM may help counteract the neuronal loss and synaptic disruption characteristic of AD.

How Does NIR Light Energy Reach the Brain?

In order to deliver NIR energy to the brain through the skull, scalp and hair to trigger photobiomodulation, this requires 3 important factors:

NIR light energy wavelengths: 810nm to 1100nm
– optimal penetrance based on the body’s optical window.
A form factor that bypasses hair and maximizes contact with the scalp
– hair absorbs light energy.
– light energy becomes weaker from distance, according to the inverse square law of light.
Sufficiently high power density/irradiance: 100+ mW/cm²
– sufficient power density/irradiance is required for light energy to penetrate the scalp and bone.

Clinical Evidence of PBM and Alzheimer’s Disease

Several preclinical studies have demonstrated the beneficial effects of PBM in animal models of AD. For instance, a study published in Neurobiology of Aging by De Taboada et al. (2011) showed that transcranial PBM reduced beta-amyloid plaques and improved memory in a mouse model of AD.^[1] Similarly, another study by Yang et al. (2018) in Neurophotonics reported that PBM decreased tau protein hyperphosphorylation and alleviated cognitive deficits in AD mice.^[2]

Clinical Research with the Vielight Neuro Gamma

The Vielight Neuro Gamma

Clinical evidence with the Vielight Neuro suggests that PBM may offer therapeutic benefits in human patients with AD.

A pilot study conducted by Saltmarche et al. (2017) with the Vielight Neuro and published in Journal of Alzheimer’s Disease found that transcranial PBM improved cognitive function and activities of daily living in patients with mild-to-moderate AD.

In 2019, Dr. Linda Chao, a professor in the Departments of Radiology, Biomedical Imaging and Psychiatry at the University of California, verified our 2015 dementia pilot trial with her own independent brain photobiomodulation dementia study with the Vielight Neuro Gamma on participants with dementia.^[2]

Eight participants diagnosed with dementia were randomized to 12 weeks of usual care or home photobiomodulation(PBM) treatments. The PBM treatments were administered at home with the Vielight Neuro Gamma, a brain photobiomodulation device that emits 100 mW/cm² of power density at 810nm and 40hz.

Several types of assessments were used:

Alzheimer’s Disease Assessment Scale-cognitive subscale and the Neuropsychiatric Inventory at baseline and 6 and 12 weeks
Magnetic resonance imaging (MRI) and resting-state functional MRI at baseline and 12 weeks.

Results:

Figure 1. ADAS-cog (A) and NPI-FS (B) scores in the PBM (blue line) and UC (red line) groups by time. Lower scores on both measures indicate better function.

After 12 weeks, there were improvements in ADAS-cog and in the NPI.

A summary measure of the individual domain scores: higher NPI-FS scores reflect more severe/more frequent dementia-related behavior.

In this study, the PBM group improved an average of -12.3 points on the NPI-FS after 6 weeks and -22.8 points after 12 weeks of treatments.

By comparison, previous pharmacological trials of donepezil reported no difference from placebo on behavioral symptoms measured by the NPI and no difference on quality of life.

Importantly, there were no adverse effects associated with the PBM treatments in this or Saltmarche et al.’s study. In contrast, many of the Food and Drug Administration approved pharmacological treatments for dementia have been associated with substantial side effect burden, such as diarrhea, vomiting, nausea, and fatigue.

Figure 2 Increased cerebral perfusion with the Vielight Neuro Gamma

The third finding of this study is that cerebral perfusion (CBF) increased after 12 weeks in the PBM group compared to the UC group. This finding is consistent with previous reports of PBM-related increases in local CBF, oxygen consumption, total hemoglobin, a proxy for increased rCBF, rCBF, and increased oxygenated/decreased deoxygenated hemoglobin concentrations.

Interestingly, the PBM-related increases in perfusion were most prominent in the parietal ROIs. This may relate to the fact that the Vielight Neuro Gamma used in this study had three transcranial LED clusters over the parietal lobe and only one transcranial LED cluster over the frontal lobe. This finding may also be explained by the report that NIR light penetrates more deeply through the parietal lobe compared to the frontal lobe due to the higher power density of the rear transcranial LED modules .

Connectivity changes in the DMN have been described in populations at risk for AD as well as in patients with AD. Because decreased DMN connectivity is a common finding in resting-state connectivity studies of AD, it is significant that there was increased functional connectivity between the PCC and the LP nodes of the DMN in the PBM group after 12 weeks compared to the UC group.

There have been reports of increased functional connectivity in the DMN after pharmacological treatments in mild-to-moderate AD patients. There have also been studies that reported changes in functional connectivity after nonpharmacological intervention in patients with MCI. To our knowledge, this is the first report of functional connectivity changes in dementia patients after a nonpharmacological intervention.

Neuro RX Gamma – Phase 3 Clinical Trial

We are running a Phase 3 Alzheimer’s Clinical Trial to test the efficacy of brain photobiomodulation via the Vielight Neuro RX Gamma (Neuro Gamma) for FDA approval. This would add to our roster of Health Canada Medical Device license for the acceleration of the recovery of upper respiratory symptoms in viral infections, such as COVID-19 with the RX-Plus (X-Plus 4).

Conclusion

Alzheimer’s disease poses a significant challenge to global health, necessitating innovative approaches for treatment and management. Brain photobiomodulation represents a promising therapeutic modality that harnesses the power of light to stimulate cellular function and promote neuroprotection. While further research is warranted, the emerging evidence suggests that PBM may offer hope for individuals living with AD and their families.

In conclusion, brain photobiomodulation holds tremendous potential as a non-invasive, safe, and effective intervention for Alzheimer’s disease. By addressing underlying pathological mechanisms and promoting neuronal health, PBM may usher in a new era of treatment for this devastating condition.

References:

De Taboada L, et al. (2011). Transcranial laser therapy attenuates amyloid-β peptide neuropathology in amyloid-β protein precursor transgenic mice. Neurobiology of Aging, 32(1), 25-28.
Yang X, et al. (2018). Transcranial low-level laser therapy improves cognitive deficits and inhibits microglial activation after controlled cortical impact in mice. Neurophotonics, 5(1), 015001.
Saltmarche AE, et al. (2017). Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report. Journal of Alzheimer’s Disease, 60(2), 1-13.
Vemuri P, Jones DT, Jack CR, Jr. Resting state functional MRI in Alzheimer’s Disease. Alzheimers Res Ther 2012;4:2
Sole-Padulles C, Bartres-Faz D, Llado A, et al. Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer’s disease. J Clin Psychopharmacol 2013;33:199–205.
Goveas JS, Xie C, Ward BD, Wu Z, Li W, Franczak M. Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer’s disease patients treated with donepezil assessed by resting-state fMRi. J Magn Reson Imaging 2011;34:764–773.
Li W, Antuono PG, Xie C, et al. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer’s disease after 12-week donepezil treatment. Neuroimage 2012;60:1083–1091.

The post Alzheimer’s Disease and Brain Photobiomodulation | Clinical Results with Vielight Neuro appeared first on Vielight Inc.

Why the nose for brain photobiomodulation?

Vielight Main — Sun, 13 Apr 2025 19:50:02 +0000

The nose is a gateway to important brain structures located at the underside of the brain, otherwise, unreachable from the scalp.

Can light energy reach the brain from the nose?

The layer of skull, just above the nasal cavity and below the brain (the cribriform plate) is extremely porous, delicate and thin. The thin, perforated structure of the cribriform plate can be as thin as 0.2 millimeters (other parts of the skull average 5-7mm). [1]

Due to its thin structure and multiple openings for olfactory nerves, the cribriform plate allows substantial 810nm light from an intranasal source to reach the olfactory system and nearby prefrontal cortex. [2]

In the context of brain photobiomodulation, this thin structure makes it very permeable for NIR energy to reach the ventral prefrontal medial cortex (vmPFC) a region of the brain located just above the nasal cavity. It is believed that in adult mammals, neurogenesis occurs only in the olfactory bulb and in the dentate gyrus of the hippocampus. [3]

Explainer animation with real skull anatomy and demonstration:

Why the Nose and Olfactory Bulb?

Photobiomodulation (PBM) delivered intranasally isn’t just about convenience, it’s about strategic access to the brain. The nose provides a direct channel to key brain regions via the cribriform plate, making it a highly efficient route for delivering near-infrared (NIR) light to areas that are crucial for cognition, emotion, and systemic regulation.

Let’s explore three major brain structures located near this nasal entry point:

1. Ventromedial Prefrontal Cortex (vmPFC)

Function:

Responsible for decision-making and risk assessment
Integrates emotional and reward-related information for complex behavioral choices

Clinical Note:
Dysfunction in the vmPFC has been associated with mood disorders, impulsivity, and impaired judgment, often seen in conditions such as depression and PTSD.

2. Olfactory Bulb

Function:

Closely linked to memory and emotion
Explains why certain smells can trigger vivid memories or emotional responses

Clinical Note:
The olfactory bulb is frequently one of the first regions affected in neurodegenerative diseases like Parkinson’s and Alzheimer’s, making it a valuable target for early intervention.

3. Hypothalamus

Function:

Acts as the brain’s master regulator of homeostasis
Controls essential functions such as temperature regulation, appetite, circadian rhythms, hormone balance, and stress response

Clinical Note:
Because of its central role in systemic regulation, the hypothalamus is an attractive therapeutic target for interventions seeking to influence brain-body balance.

Key Functions of the vmPFC

Emotion Regulation: The vmPFC helps modulate emotional responses, often interacting with the amygdala, which is involved in processing emotions like fear and aggression. It helps downregulate excessive emotional responses.
Decision-Making: This region is critical for value-based decision-making, where choices are made based on the predicted value of different outcomes. It weighs rewards, punishments, and social factors in decision processes.
Social Cognition: The vmPFC contributes to understanding social norms, empathy, and moral reasoning. It helps individuals make appropriate social decisions and understand the feelings and intentions of others.
Memory Integration: It integrates emotional and social information from past experiences to guide future behavior and decisions.

Vielight Patented Intranasal Technology

Our patented intranasal technology enables NIR light energy to diffuse through the nasal channel, to the brain’s vMPFC, which is a crucial component of the Default Mode Network.

Watch this demonstration with Vielight intranasal technology on a real human skull:

Figure 1: Vielight Intranasal

Penetration of NIR energy through the nasal channel through the cribriform plate.

References

Gomez J, Pickup S. Cribriform Plate Fractures. [Updated 2023 Jun 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562192/#
Erdem G, Erdem T, Miman MC, Ozturan O. A radiological anatomic study of the cribriform plate compared with constant structures. Rhinology. 2004 Dec;42(4):225-9. PMID: 15626256.
Bergmann O, Spalding KL, Frisén J. Adult Neurogenesis in Humans. Cold Spring Harb Perspect Biol. 2015 Jul 1;7(7):a018994. doi: 10.1101/cshperspect.a018994. PMID: 26134318; PMCID: PMC4484963.
Wilson RS, Yu L, Bennett DA. Odor identification and mortality in old age. Chem Senses. 2011 Jan;36(1):63-7. doi: 10.1093/chemse/bjq098. Epub 2010 Oct 5. PMID: 20923931; PMCID: PMC3002399.

The post Why the nose for brain photobiomodulation? appeared first on Vielight Inc.

MCI and Brain Photobiomodulation | Clinical Results with Vielight Neuro

Vielight Main — Tue, 14 Jan 2025 21:25:39 +0000

Mild Cognitive Impairment (MCI) is a condition that often precedes more severe forms of dementia, such as Alzheimer’s disease (AD).

A recent clinical study by researchers from the University of Toronto investigated whether a non-invasive technique called transcranial photobiomodulation (tPBM), which uses near-infrared light to stimulate brain cells, could improve brain function in individuals with MCI. The study utilized the Vielight Neuro RX Gamma (medical version of the Vielight Neuro Gamma), a cutting-edge device designed to deliver transcranial and intranasal PBM therapy.

FULL DATA PRESENTATION LINK

What is Transcranial Photobiomodulation (tPBM)?

tPBM is a non-invasive treatment that uses near-infrared light to penetrate the skull and stimulate brain cells. This light energy is thought to enhance mitochondrial function—the powerhouse of cells—which can improve energy production and overall Brain wellness. The Vielight Neuro RX Gamma is a specialized device that delivers this light therapy directly to the brain through the scalp and nasal cavity, making it a convenient tool for home-based treatment.

The Study Design

The study involved 14 participants with MCI, who were randomly assigned to either an active tPBM group or a sham (placebo) group. Over six weeks, participants used the Vielight Neuro RX Gamma daily at home. The active group received real near-infrared light therapy, while the sham group received a placebo treatment with no therapeutic effect. Before and after the six-week period, participants underwent a series of tests to measure changes in brain function, including:

Cognitive tests: Trail Making Test (TMT) and Mini-Mental State Examination (MMSE) to assess executive function and general cognitive abilities.
Brain imaging: Structural MRI, resting-state functional MRI (rsfMRI), and Proton Magnetic Resonance Spectroscopy (H-MRS) to evaluate brain structure, connectivity, and metabolic changes.
Blood tests: Analysis of biomarkers related to Alzheimer’s disease and mitochondrial function.

Key Findings

The results showed significant improvements in the active tPBM group compared to the sham group:

Cognitive Function: Participants in the active group performed better on the Trail Making Test (TMT-B), which measures executive function, and showed a trend toward improvement on the MMSE, a general cognitive test.
Brain wellness:
- H-MRS scans revealed a decline in the N-acetyl aspartate to total creatine ratio (NAA/Cr), a marker of neuronal health, suggesting improved brain metabolism.
- Structural MRI showed an increase in the volume of the right thalamus, a brain region involved in sensory and motor signaling.
- Resting-state fMRI demonstrated enhanced connectivity in key brain networks, including the default mode network (DMN) and limbic network, which are critical for memory and emotional processing.
Blood Biomarkers:
- Levels of isoleucine, methionine, and sarcosine—markers linked to Alzheimer’s and amyloid plaque formation—decreased significantly.
- Levels of butyrate and L-carnitine—markers associated with improved mitochondrial function—increased, indicating better cellular energy production.
Plasma Tau: While not statistically significant, there was a notable reduction in plasma tau levels in the active group. Tau is a protein linked to Alzheimer’s progression, and its reduction is a promising sign.

What Does This Mean?

The findings suggest that tPBM, delivered via the Vielight Neuro RX Gamma, may improve executive function, brain connectivity, and mitochondrial health while reducing markers associated with Alzheimer’s disease. These results are particularly exciting because they highlight the potential of a non-invasive, home-based therapy to slow or even reverse cognitive decline in individuals with MCI.

Limitations and Future Directions

While the results are promising, this was a small pilot study with only 14 participants. Larger studies are needed to confirm these findings and explore the long-term effects of tPBM. Additionally, future research could investigate whether tPBM can delay or prevent the progression from MCI to Alzheimer’s dementia.

Conclusion

This study offers hope for individuals with MCI and their families, suggesting that near-infrared light therapy, such as that delivered by the Vielight Neuro RX Gamma, could be a safe and effective way to improve brain function and potentially slow the progression of cognitive decline. As research continues, tPBM may become a valuable tool in the fight against Alzheimer’s disease and other forms of dementia.

This study represents an exciting step forward in the field of non-invasive brain therapies, and the Vielight Neuro RX Gamma stands out as a promising device for delivering these benefits.

The post MCI and Brain Photobiomodulation | Clinical Results with Vielight Neuro appeared first on Vielight Inc.

Research on Microtubulin with Vielight technology | Implications for Alzheimer’s Disease

Vielight Main — Thu, 08 Aug 2024 20:14:54 +0000

The effects of 810nm energy from the Vielight Neuro on microtubulin

This new groundbreaking study with Vielight technology conducted in partnership with the Department of Mechanical and Aerospace Engineering University of Turin and the University of Alberta explores the effects of 810nm NIR energy on crucial cellular structures known as tubulin.

Healthy cellular function and structure are intrinsically linked to the integrity of tubulins. Tubulins are proteins found in all eukaryotic cells and play a critical role in their structure and function. Eukaryotic cells typically contain 3–4% tubulin. Notably, however, mammalian brain tissue is particularly rich in tubulin content, consisting of 10% or more of the total protein content.

Tubulin, crucial in Alzheimer’s pathology, was studied for PBM’s effects using Raman spectroscopy. Tubulin samples exposed to pulsed NIR radiation with Vielight LED technology (810 nm, 10 Hz, 22.5 J/cm²) revealed significant changes in protein structures.

Using this validated imaging method, statistically significant alterations in the secondary structures of polymerized NIR-exposed tubulin were observed, characterized by a notable decrease in α-helix content and a concurrent increase in β-sheets compared to the control samples.

This newly discovered mechanism with Vielight technology could have implications for reducing the risks associated with brain aging, including neurodegenerative diseases like Alzheimer’s disease, through the introduction of an intervention following this transition. and potential for brain aging intervention.

The post Research on Microtubulin with Vielight technology | Implications for Alzheimer’s Disease appeared first on Vielight Inc.

Vielight Featured in USA Today!

Vielight Main — Wed, 24 Jan 2024 19:47:53 +0000

Vielight featured in USA Today for Alzheimer’s and Parkinsons’ Research!

We were recently featured in USA Today! This independent article covers the modern day challenges that humanity faces and how our Vielight Neuro is being used in cutting-edge photobiomodulation research to study the effects of optimized, high-powered NIR energy delivery to the brain.

This article also covers research done with our Neuro on Parkinsons’ by Dr. Liebert from the University of Sydney and our 228-participant Alzheimer’s trial.

We’d like to extend a heartfelt thank you to the researchers and supporters that have used our technology over the years.

Read the full article here: Link

The post Vielight Featured in USA Today! appeared first on Vielight Inc.

Brain Photobiomodulation: A Potential Drug-Free Option for Alzheimer’s Therapy

Vielight Main — Mon, 24 Jul 2023 23:32:50 +0000

Brain Photobiomodulation: A Drug-Free Alternative for Treating Alzheimer’s Disease

Alzheimer’s disease, a progressive neurodegenerative disorder, poses one of the greatest challenges to modern medicine. With its devastating impact on cognitive function and quality of life, finding effective treatments has become an urgent priority. As traditional pharmacological therapies struggle to provide a definitive cure, alternative approaches are gaining attention. Among these emerging options, brain photobiomodulation shows promising potential as a drug-free alternative for treating Alzheimer’s disease.

Understanding Alzheimer’s Disease: The Need for Novel Approaches

Alzheimer’s disease is characterized by the accumulation of amyloid-beta plaques and tau protein tangles in the brain, leading to the loss of neurons and cognitive decline. Conventional drug therapies primarily target these pathological hallmarks, but their success in halting disease progression remains limited. Additionally, some medications come with adverse side effects, leaving patients and their caregivers in search of safer and more effective alternatives.

Enter Brain Photobiomodulation: Shedding Light on Hope

Brain photobiomodulation, also known as transcranial photobiomodulation (tPBM) or low-level light therapy, involves applying specific wavelengths of light to the scalp to stimulate cellular function within the brain. This non-invasive technique has gained traction as a potential therapeutic tool for various neurological conditions, including Alzheimer’s disease.

How Brain Photobiomodulation Works

During brain photobiomodulation, near-infrared light is delivered to targeted areas of the brain. This light penetrates the skull and is absorbed by mitochondria within neurons and other cells. Mitochondria, often referred to as the “powerhouses” of cells, produce adenosine triphosphate (ATP), which is essential for cellular energy and function. By enhancing mitochondrial activity, brain photobiomodulation promotes cellular health and can have beneficial effects on neuronal function and communication.

Promising Research and Results

Preliminary studies investigating the effects of brain photobiomodulation on Alzheimer’s disease have shown encouraging outcomes. Researchers have observed improvements in cognitive performance, memory, and learning abilities in animal models with Alzheimer’s-like pathology. Human clinical trials are ongoing and have reported positive trends, suggesting that brain photobiomodulation may slow cognitive decline and improve certain aspects of memory in individuals with mild cognitive impairment or early-stage Alzheimer’s disease.

Potential Mechanisms of Action

The exact mechanisms by which brain photobiomodulation exerts its therapeutic effects on Alzheimer’s disease are still being explored. Some proposed mechanisms include:

Reduction of Neuroinflammation: Brain photobiomodulation may help reduce inflammation in the brain, which is known to play a significant role in the progression of Alzheimer’s disease.
Enhancement of Blood Flow: By improving blood flow and vascular function, brain photobiomodulation may support the delivery of nutrients and oxygen to brain cells, aiding their survival and function.
Stimulation of Brain Plasticity: Brain photobiomodulation might enhance neuroplasticity, the brain’s ability to reorganize and form new connections, which could lead to cognitive improvements.

Safety and Accessibility

One of the major advantages of brain photobiomodulation is its non-invasiveness and lack of reported serious side effects. It offers a drug-free approach that is relatively safe and well-tolerated, making it an attractive option for individuals seeking alternatives to traditional medications.

Moreover, the equipment required for brain photobiomodulation is becoming increasingly accessible, with portable devices available for home use. However, it is crucial to consult with healthcare professionals before using such devices to ensure proper usage and safety.

The Way Forward: Expanding Research and Awareness

While brain photobiomodulation shows great promise as a drug-free alternative for treating Alzheimer’s disease, it is essential to recognize that research in this area is still in its early stages. More comprehensive clinical trials and long-term studies are needed to establish the therapy’s efficacy and safety conclusively.

Published Brain Photobiomodulation Research for Alzheimer’s and Dementia with Vielight technology

In 2015, our dementia pilot trial made history by being the first to show efficacy of brain photobiomodulation (PBM) for dementia in humans with a home-use device.^[1]

In 2019, Dr. Linda Chao, a professor in the Departments of Radiology, Biomedical Imaging and Psychiatry at the University of California, verified our 2015 dementia pilot trial with her own independent brain photobiomodulation study with the Vielight Neuro Gamma on participants with dementia.^[2]

Several types of assessments were used:

Alzheimer’s Disease Assessment Scale-cognitive subscale and the Neuropsychiatric Inventory at baseline and 6 and 12 weeks
Magnetic resonance imaging (MRI) and resting-state functional MRI at baseline and 12 weeks.

Results:

Figure 1. ADAS-cog (A) and NPI-FS (B) scores in the PBM (blue line) and UC (red line) groups by time. Lower scores on both measures indicate better function.

After 12 weeks, there were improvements in ADAS-cog and in the NPI.

A summary measure of the individual domain scores: higher NPI-FS scores reflect more severe/more frequent dementia-related behavior.

In this study, the PBM group improved an average of -12.3 points on the NPI-FS after 6 weeks and -22.8 points after 12 weeks of treatments.

By comparison, previous pharmacological trials of donepezil reported no difference from placebo on behavioral symptoms measured by the NPI and no difference on quality of life.^[3]

Figure 2 Increased cerebral perfusion with the Vielight Neuro Gamma

The third finding of this study is that cerebral perfusion (CBF) increased after 12 weeks in the PBM group compared to the UC group. This finding is consistent
with previous reports of PBM-related increases in local CBF, oxygen consumption, total hemoglobin, a proxy for increased rCBF, rCBF, and increased oxygenated/decreased deoxygenated hemoglobin concentrations.

Connectivity changes in the DMN have been described in populations at risk for AD as well as in patients with AD. Because decreased DMN connectivity is a common finding in resting-state connectivity studies of AD,^[4] it is significant that there was increased functional connectivity between the PCC and the LP nodes of the DMN in the PBM group after 12 weeks compared to the UC group.

There have been reports of increased functional connectivity in the DMN after pharmacological treatments in mild-to-moderate AD patients.^[5-9] There have also been studies that reported changes in functional connectivity after nonpharmacological intervention in patients with MCI.^[10-12] To our knowledge, this is the first report of functional connectivity changes in dementia patients after a nonpharmacological intervention.

References

[1] Saltmarche AE, Naeser MA, Ho KF, Hamblin MR, Lim L. Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report. Photomed Laser Surg. 2017 Aug;35(8):432-441. doi: 10.1089/pho.2016.4227. Epub 2017 Feb 10. PMID: 28186867; PMCID: PMC5568598.

[2] Chao LL. Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial. Photobiomodul Photomed Laser Surg. 2019 Mar;37(3):133-141. doi: 10.1089/photob.2018.4555. Epub 2019 Feb 13. PMID: 31050950.

[3] Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2018;6:CD001190

[4] Vemuri P, Jones DT, Jack CR, Jr. Resting state functional MRI in Alzheimer’s Disease. Alzheimers Res Ther 2012;4:2

[5] Sole-Padulles C, Bartres-Faz D, Llado A, et al. Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer’s disease. J Clin Psychopharmacol 2013;33:199–205.

[6] Goveas JS, Xie C, Ward BD, Wu Z, Li W, Franczak M. Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer’s disease patients treated with donepezil assessed by resting-state fMRi. J Magn Reson Imaging 2011;34:764–773.

[7] Li W, Antuono PG, Xie C, et al. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer’s disease after 12-week donepezil treatment. Neuroimage 2012;60:1083–1091.

[8] Blautzik J, Keeser D, Paolini M, et al. Functional connectivity increase in the default-mode network of patients with Alzheimer’s disease after long-term treatment with galantamine. Eur Neuropsychopharmacol 2016;26:602–613.

[9] Lorenzi M, Beltramello A, Mercuri NB, et al. Effect of memantine on resting state default mode network activity in Alzheimer’s disease. Drugs Aging 2011;28:205–217

[10] Chirles TJ, Reiter K, Weiss LR, Alfini AJ, Nielson KA, Smith JC. Exercise training and functional connectivity changes in mild cognitive impairment and healthy elders. J Alzheimers Dis 2017;57:845–856.

[11] Suo C, Singh MF, Gates N, et al. Therapeutically relevant structural and functional mechanisms triggered by physical and cognitive exercise. Mol Psychiatry 2016;21:1645.

[12] Wells RE, Kerr CE, Wolkin J, et al. Meditation for adults with mild cognitive impairment: a pilot randomized trial. J Am Geriatr Soc 2013;61:642–645.

The post Brain Photobiomodulation: A Potential Drug-Free Option for Alzheimer’s Therapy appeared first on Vielight Inc.

40Hz Gamma Neuromodulation in Alzheimer’s Research | Brain Photobiomodulation and Visual Cortex Stimulation

Vielight Main — Wed, 31 May 2023 15:06:58 +0000

The Ongoing Search for Effective and Accessible Treatments for Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common type of dementia in elderly individuals worldwide (Wilson et al., 2012). The disease is characterized by neurodegeneration, tissue changes in the brain, (including amyloid-containing plaques and tangles of hyperphosphorylated tau protein), severe cognitive decline and in many cases, neuropsychiatric symptoms. The search for effective, safe and accessible treatments remains largely elusive. The currently approved drugs have considerable side effects, reducing compliance and some require increased medical follow-up and brain imaging, reducing the accessibility of the treatment to many.

Gamma Modulation as a Potential Treatment for Alzheimer’s Disease

Brain cells, also known as neurons, communicate with each other through electrical signals that produce patterns called brain waves. Of the 5 different types of brain waves, gamma waves are the fastest brain waves. They range from 30 to 100 Hez. Gamma brain waves are linked to cognitive functioning, learning, memory, and information processing.

Abnormal brain waves have been observed in humans with Alzheimer’s Disease (AD), including decreased power of Gamma waves.

In a landmark study, MIT demonstrated that 40Hz visual flashing resulted in improvements in memory and learning in a mouse model of AD. Decreased amyloid plaques and less brain atrophy were also noted. This 40Hz modulation is believed to increase non-inflammatory microglia, which work to remove the pathological amyloid plaque buildup. Additionally, 40 Hz modulation may increase the decreased levels of gamma in patients with AD.

Delivering Gamma Neuromodulation via Brain Photobiomodulation

Photobiomodulation is an innovative way to modulate gamma waves in the brain. The Vielight Neuro Gamma is the first and remains the only commercially-available brain photobiomodulation device to demonstrate statistically significant neuromodulation. This is attributable to our Vie-LED technology, which delivers a laser-like irradiance on key brain networks.

FULL NEUROMODULATION STUDY WITH VIELIGHT NEURO GAMMA

The key randomized, sham-controlled study demonstrated that delivery of 40Hz 810nm NIR energy on using the Vielight Neuro Gamma significantly increases the power of the higher oscillatory frequencies of gamma, alpha and beta and reduces the power of the slower frequencies of delta and theta in subjects in resting state. These changes were seen after a single session of PBM with the Neuro Gamma and were significantly different when compared to sham stimulation.[1] This study clearly demonstrated that 40 Hz pulsed PBM is able to modulate neuronal oscillations and increase the power of gamma in the brain.

In further support of the benefits of 40 Hz pulsed PBM for patients with AD, an independent study conducted by the The University of California San Francisco demonstrated that 12 weeks of at-home use of the Neuro Gamma in dementia patients produced improvements in mental acuity, increased cerebral perfusion and increased connectivity between the posterior cingulate cortex and lateral parietal nodes within the Default-Mode network [2].

The other benefits of brain photobiomodulation

While there are multiple ways to produce neuromodulation and increase levels of gamma in the brain, neuromodulation through pulsed photobiomodulation produces additional benefits not provided by other modalities, that would be of significant benefit to patients with AD.

Improved Mitochondrial Function

Photobiomodulation has been shown to improve mitochondrial function, resulting in increased ATP production. Mitochondrial dysfunction occurs very early in the pathogenesis of AD, and preventing this dysregulation via PBM may be of significant benefit for individuals with AD, as well as those at risk of developing AD.

Increased Blood Flow

PBM results in increased release of Nitric Oxide (NO). NO is a powerful neurotransmitter with multiple properties, one of which being vasodilation. This has been linked with increased oxygenation in the brain.

Improved Neuroprotection

A wide variety of evidence suggests that PBM can be utilized for neuroprotection as a pre-emptive measure to protect cells from future damage and reduce ongoing damage and promote their survival and longevity. [3,4,5,6]

Increased Neurogenesis and Synaptogenesis

Brain photobiomodulation has been shown to promote both synaptogenesis and neurogenesis, as evidenced through increased levels of brain derive neurotrophic factor (BDNF). [7,8]

Conclusion

Neuromodulation to increase gamma oscillations in the brain appears to produce significant clinical benefits for AD. While such neuromodulation may be achieved in more than one way, 40Hz neuromodulation via PBM has been shown to produce additional cellular benefits that are of particular relevance to patients with AD.

References

[1] Zomorrodi, Reza & Loheswaran, Genane & Pushparaj, Abhiram & Lim, Lew. (2019). Pulsed Near Infrared Transcranial and Intranasal Photobiomodulation Significantly Modulates Neural Oscillations: a pilot exploratory study. Scientific Reports. 9. 10.1038/s41598-019-42693-x.

[3] Liang J, Liu L, Xing D. Photobiomodulation by low-power laser irradiation attenuates Abeta-induced cell apoptosis through the Akt/GSK3beta/beta-catenin pathway. Free Radic Biol Med. 2012;53:1459–1467. [PubMed] [Google Scholar][4] Eells JT, Henry MM, Summerfelt P, Wong-Riley MT, Buchmann EV, Kane M, Whelan NT, Whelan HT. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc Natl Acad Sci U S A. 2003;100:3439–3444

[5] Wong-Riley MT, Liang HL, Eells JT, Chance B, Henry MM, Buchmann E, Kane M, Whelan HT. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase

[6] Huang YY, Nagata K, Tedford CE, Hamblin MR. Low-level laser therapy (810 nm) protects primary cortical neurons against excitotoxicity in vitro. J Biophotonics. 2014;7:656–664. [PMC free article] [PubMed] [Google Scholar][7] Meng C, He Z, Xing D. Low-level laser therapy rescues dendrite atrophy via upregulating BDNF expression: implications for Alzheimer’s disease. J Neurosci. 2013;33:13505–13517. [PMC free article] [PubMed] [Google Scholar][8] YYW Huang Q, Xuan W, Ando T, Xu T, Sharma SK, Kharkwal GB, Hamblin MR. Low Level Light Therapy for Traumatic Brain Injury [Google Scholar]

The post 40Hz Gamma Neuromodulation in Alzheimer’s Research | Brain Photobiomodulation and Visual Cortex Stimulation appeared first on Vielight Inc.

Dementia and Brain Photobiomodulation

Vielight Main — Tue, 11 Apr 2023 21:02:59 +0000

In 2015, our dementia pilot trial made history by being the first to show efficacy of brain photobiomodulation (PBM) for dementia in humans with a home-use device, the Vielight Neuro Gamma.^[1]

Several types of assessments were used:

Alzheimer’s Disease Assessment Scale-cognitive subscale and the Neuropsychiatric Inventory at baseline and 6 and 12 weeks
Magnetic resonance imaging (MRI) and resting-state functional MRI at baseline and 12 weeks.